These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 28737403)

  • 1. Validation of Dissolution Testing with Biorelevant Media: An OrBiTo Study.
    Mann J; Dressman J; Rosenblatt K; Ashworth L; Muenster U; Frank K; Hutchins P; Williams J; Klumpp L; Wielockx K; Berben P; Augustijns P; Holm R; Hofmann M; Patel S; Beato S; Ojala K; Tomaszewska I; Bruel JL; Butler J
    Mol Pharm; 2017 Dec; 14(12):4192-4201. PubMed ID: 28737403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biorelevant dissolution testing of a weak base: Interlaboratory reproducibility and investigation of parameters controlling in vitro precipitation.
    Berben P; Ashworth L; Beato S; Bevernage J; Bruel JL; Butler J; Dressman J; Schäfer K; Hutchins P; Klumpp L; Mann J; Nicolai J; Ojala K; Patel S; Powell S; Rosenblatt K; Tomaszewska I; Williams J; Augustijns P
    Eur J Pharm Biopharm; 2019 Jul; 140():141-148. PubMed ID: 31051249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Similarity of dissolution profiles from biorelevant media: Assessment of interday repeatability, interanalyst repeatability, and interlaboratory reproducibility using ibuprofen and ketoconazole tablets.
    Jamil R; Xu T; Shah HS; Adhikari A; Sardhara R; Nahar K; Morris KR; Polli JE
    Eur J Pharm Sci; 2021 Jan; 156():105573. PubMed ID: 32987114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dissolution testing of modified release products with biorelevant media: An OrBiTo ring study using the USP apparatus III and IV.
    Reppas C; Vrettos NN; Dressman J; Andreas CJ; Miyaji Y; Brown J; Etherson K; Hanley S; Karkossa F; Karlsson E; Klein S; Maier GM; McAllister M; Mistry N; Rosenblatt K; Schäfer KJ; Smith KL; Tomaszewska I; Williams J; Winge F; Vertzoni M
    Eur J Pharm Biopharm; 2020 Nov; 156():40-49. PubMed ID: 32882421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction between fed gastric media (Ensure Plus®) and different hypromellose based caffeine controlled release tablets: comparison and mechanistic study of caffeine release in fed and fasted media versus water using the USP dissolution apparatus 3.
    Franek F; Holm P; Larsen F; Steffansen B
    Int J Pharm; 2014 Jan; 461(1-2):419-26. PubMed ID: 24342711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Coadministered Water on the In Vivo Performance of Oral Formulations Containing N-Acetylcysteine: An In Vitro Approach Using the Dynamic Open Flow-Through Test Apparatus.
    Sager M; Schneider F; Jedamzik P; Wiedmann M; Schremmer E; Koziolek M; Weitschies W
    Mol Pharm; 2017 Dec; 14(12):4272-4280. PubMed ID: 29064257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of reduced gastric acid secretion on dissolution of salts of weak bases in the fasted upper gastrointestinal lumen: Data in biorelevant media and in human aspirates.
    Litou C; Vertzoni M; Xu W; Kesisoglou F; Reppas C
    Eur J Pharm Biopharm; 2017 Jun; 115():94-101. PubMed ID: 28214603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dissolution Profile of Mefenamic Acid Solid Dosage Forms in Two Compendial and Biorelevant (FaSSIF) Media.
    Nurhikmah W; Sumirtapura YC; Pamudji JS
    Sci Pharm; 2016; 84(1):181-90. PubMed ID: 27110508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance Evaluation of Montelukast Pediatric Formulations: Part I-Age-Related In Vitro Conditions.
    Guimarães M; Somville P; Vertzoni M; Fotaki N
    AAPS J; 2022 Jan; 24(1):26. PubMed ID: 35013835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integration of Biorelevant Pediatric Dissolution Methodology into PBPK Modeling to Predict In Vivo Performance and Bioequivalence of Generic Drugs in Pediatric Populations: a Carbamazepine Case Study.
    Pawar G; Wu F; Zhao L; Fang L; Burckart GJ; Feng K; Mousa YM; Al Shoyaib A; Jones MC; Batchelor HK
    AAPS J; 2023 Jun; 25(4):67. PubMed ID: 37386339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding the in vivo performance of enteric coated tablets using an in vitro-in silico-in vivo approach: case example diclofenac.
    Kambayashi A; Blume H; Dressman J
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1337-47. PubMed ID: 24056057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and Validation of Sample Preparation and an HPLC Analytical Method for Dissolution Testing in Fed-State Simulated Gastric Fluid-Illustrating Its Application for Ibuprofen and Ketoconazole Immediate Release Tablets.
    Shah HS; Sardhara R; Nahar K; Xu T; Delvadia P; Siddiqui A; Gao Z; Selen A; Morris K
    AAPS PharmSciTech; 2020 Jun; 21(5):172. PubMed ID: 32533366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Dissolution Medium pH and Simulated Gastrointestinal Contraction on Drug Release From Nifedipine Extended-Release Tablets.
    Gao Z; Ngo C; Ye W; Rodriguez JD; Keire D; Sun D; Wen H; Jiang W
    J Pharm Sci; 2019 Mar; 108(3):1189-1194. PubMed ID: 30343136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of the Oral Pharmacokinetics and Food Effects of Gabapentin Enacarbil Extended-Release Tablets Using Biorelevant Dissolution Tests.
    Yamaguchi Ikeuchi S; Kambayashi A; Kojima H; Oku N; Asai T
    Biol Pharm Bull; 2018; 41(11):1708-1715. PubMed ID: 30381671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biorelevant dissolution media as a predictive tool for glyburide a class II drug.
    Wei H; Löbenberg R
    Eur J Pharm Sci; 2006 Sep; 29(1):45-52. PubMed ID: 16815694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dissolution of a Biopharmaceutics Classification System Class II Free Acid from Immediate Release Tablets Containing a Microenvironmental pH Modulator: Comparison of a Biorelevant Bicarbonate Buffering System with Phosphate Buffers.
    Haznar-Garbacz D; Hoc D; Garbacz G; Lachman M; Słomińska D; Romański M
    AAPS PharmSciTech; 2022 Jul; 23(6):203. PubMed ID: 35882674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Dissolution in the Lower Intestine and Its Impact on the Absorption Process of High Dose Low Solubility Drugs.
    Georgaka D; Butler J; Kesisoglou F; Reppas C; Vertzoni M
    Mol Pharm; 2017 Dec; 14(12):4181-4191. PubMed ID: 28366005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A physiologically-based drug absorption modeling for orally disintegrating tablets.
    Kambayashi A; Kiyota T
    Eur J Pharm Biopharm; 2020 Jul; 152():1-9. PubMed ID: 32371153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and application of a biorelevant dissolution method using USP apparatus 4 in early phase formulation development.
    Fang JB; Robertson VK; Rawat A; Flick T; Tang ZJ; Cauchon NS; McElvain JS
    Mol Pharm; 2010 Oct; 7(5):1466-77. PubMed ID: 20701327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biorelevant Dissolution Models for a Weak Base To Facilitate Formulation Development and Overcome Reduced Bioavailability Caused by Hypochlordyria or Achlorhydria.
    Kou D; Dwaraknath S; Fischer Y; Nguyen D; Kim M; Yiu H; Patel P; Ng T; Mao C; Durk M; Chinn L; Winter H; Wigman L; Yehl P
    Mol Pharm; 2017 Oct; 14(10):3577-3587. PubMed ID: 28834434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.